NCBiotech News

Burlington-based LabCorp has developed the first testing method to simultaneously detect for COVID-19, influenza A / B, and respiratory syncytial virus (RSV) just in time for the upcoming flu season.

NC bioscience companies getting federal SBIR/STTR R&D funding will soon have a chance to win matching funds from the state, thanks to new funding for the One NC Small Business Program.

San Diego-based Illumina, which founded GRAIL in 2016 and then spun it off as a standalone business, is now buying the unique cancer-testing company, with plans for a Durham factory, for $8 billion.

The University of North Carolina at Chapel Hill and BASF Corporation are joining forces to address global challenges.

Syngenta has donated four custom plant growth chambers valued at $1.5 million to NC State's Plant Sciences Initiative.

RTP medical device company TransEnterix is establishing the first Asia-Pacific training center for its Senhance Surgical System at the Saitama Medical University International Center in Tokyo.

Biogen announces a $250 million, 20-year initiative – Healthy Climate, Healthy Lives – to eliminate fossil fuel emissions across all its operations by 2040.

The innovative California-based cancer-detection company GRAIL, Inc., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public.

Raleigh-based AgEye Technologies, which typically provides its indoor farming customers AI-powered cameras, sensors and predictive analytics, has added its pandemic-beating “plant scientist in a box” to its portfolio.

A researcher in the Brody School of Medicine at East Carolina University is using an NCBiotech grant to study the human and environmental safety of NoPest, an ECU-created novel pesticide aimed at mosquito control.

Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.

Durham’s BioCryst Pharmaceuticals has landed a new federal contract totaling $44 million and added some $3 million to an existing contract to support the development of galidesivir as a possible COVID-19 treatment.

bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.

News of the first U.S. coronavirus case hit the American public on Tuesday, Jan. 21. For Jessilyn Dunn, PhD, assistant professor in the Departments of Biomedical Engineering and Biostatistics and Bioinformatics at Duke University and director of the Duke BIG IDEAs Lab, the infection in Washington State was a cue to launch a new study⁠—CovIdentify.

RTP's APIE Therapeutics has signed a licensing agreement with RTI International to develop a class of RTI-developed compounds targeting heart failure and lung disease.